NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3

Events
Written By Stine Krag Brunvold

Neuromuscular Junction Transmission Failure in Sarcopenia

CEO, Thomas Holm Pedersen, PhD, NMD Pharma, Aarhus, (Denmark).
Investigating ClC-1 chloride channel inhibition as a therapeutic strategy for sarcopenia.
See the ICFSR program here:

Stine Krag Brunvold
Previous

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 2
Next

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&A